CFM
KRYS icon

Catalyst Funds Management’s Krystal Biotech KRYS Stock Holding History

Catalyst Funds Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-400
Closed -$71.2K – 1390
2024
Q1 		$71.2K Buy
+400
New +$55.6K 0.02% 478

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Catalyst Funds Management's KRYS Position: Q2 2024 in Review

Catalyst Funds Management sold out of Krystal Biotech (KRYS) in Q2 2024, closing a stake of 400 shares — an estimated $71.2K sold.

Catalyst Funds Management first reported a position in KRYS in Q1 2024 and held it in 1 quarter. The position peaked at $71.2K in Q1 2024. 245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

  • Catalyst Funds Management reported no remaining Krystal Biotech position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 400 Krystal Biotech shares in Q2 2024, an estimated $71.2K.
  • Catalyst Funds Management first reported a position in Krystal Biotech in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Krystal Biotech position peaked at $71.2K in Q1 2024.
  • 245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.